Sugi Predict
/ Targets
/ SMARCC2
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to SMARCC2 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) |
PHASE3 | RECRUITING |
| Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment |
PHASE2/PHASE3 | RECRUITING |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) |
PHASE2 | COMPLETED |
| Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma |
PHASE2 | RECRUITING |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. |
PHASE2 | RECRUITING |
| A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer. |
PHASE2 | NOT_YET_RECRUITING |
| PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS |
PHASE2 | COMPLETED |
| Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial |
PHASE2 | SUSPENDED |
| Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers |
PHASE1/PHASE2 | COMPLETED |
| Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer |
PHASE1 | RECRUITING |
| Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma |
PHASE1 | COMPLETED |
| Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load |
PHASE1 | COMPLETED |
| Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients |
nan | RECRUITING |
| Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics |
nan | UNKNOWN |
| PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia |
nan | UNKNOWN |
| Implementation of FEES in Spinal Muscle Atrophy |
nan | COMPLETED |
| Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer |
nan | UNKNOWN |
| CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma |
nan | UNKNOWN |
| Cancer in Inherited Bone Marrow Failure Syndromes |
nan | RECRUITING |
| Newborn Screening for Spinal Muscular Atrophy |
nan | COMPLETED |
| Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus |
nan | COMPLETED |
| HIV and Other Risk Factors for Esophageal Squamous Cell Carcinoma in Malawi |
nan | COMPLETED |
| Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome |
nan | COMPLETED |
| Motor Development and Orthoses in Spinal Muscular Atrophy (SMA) |
nan | COMPLETED |
| Mayo AVC Registry and Biobank |
nan | RECRUITING |
| A Pilot Study of Biomarkers for Spinal Muscular Atrophy |
nan | COMPLETED |
| Natural History Study of Smith-Magenis Syndrome |
nan | ACTIVE_NOT_RECRUITING |
Related proteins — ESM-2 sequence neighbours (a SMARCC2 binder may also engage these)